TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06006169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: BL-B01D1 was administered by intravenous infusion on D1, D8, or D1 in 3-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: SI-B003 was administered intravenously every 3 weeks (Q3W).
Study: NCT06207656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBC
Description: Patients will receive the following per 28-day cycle:~* Encorafenib: 300 mg (4 × 75 mg oral capsule) daily (QD)~* Binimetinib: 45 mg (3 × 15 mg oral tablet) twice daily (BID)~* Cetuximab: 500 mg/m2 every 2 weeks as per standard institutional practice.
Study: NCT06279468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intervertebral disc release
Description: After standard posterior instrumentation and fusion in scoliosis cases, Ponte osteotomies are performed on vertebrae with a Nash-Moe classification of 1 degree or higher. The intervertebral discs on the convex side of the scoliosis, situated between the vertebrae that have undergone Ponte osteotomy, will be approached and incised parallel to the intervertebral space. The intervertebral disc and endplate cartilage were incised and separated using reamers. Subsequently, the intervertebral space was expanded and irrigated, and the fragments of the intervertebral disc were extracted using nucleus pulposus forceps. Impacting bone graft into the intervertebral space, thus sustaining the optimal height of intervertebral space.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ponte osteotomy
Description: After standard posterior instrumentation and fusion in scoliosis cases, Ponte osteotomies are performed on vertebrae with a Nash-Moe classification of 1 degree or higher. Subsequent corrective procedures can be performed immediately following Ponte osteotomy completion. The deformity was corrected using the bilateral rod rotation and segmental derotation technique after inserting rods. Under fluoroscopic guidance, compression, distraction, and in situ bending maneuvers were implemented as needed. Allograft bone material was utilized for the purpose of bone fusion
Study: NCT05563961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panadol®
Description: Reference Drug. Multiple-dose stage: Cohort 1, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SafeTynadol®
Description: Test Drugs. Multiple-dose stage:~Cohort 2, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg) Cohort 3, 3 tablets at first dosage and 2 tablets at second to forth dosage Q6H (total 4 dosages, 9 tablets or 4,500 mg) Cohort 4, 3 tablets at first to second dosage and 2 tablets at third to forth dosage Q6H (total 4 dosages, 10 tablets or 5,000 mg) Cohort 5, 3 tablets Q6H (total 4 dosages, 12 tablets or 6,000 mg) Cohort 6, 4 tablets Q6H (total 4 dosages, 16 tablets or 8,000 mg) Cohort 7, 5 tablets Q6H (total 4 dosages, 20 tablets or 10,000 mg) Cohort 8, 6 tablets Q6H (total 4 dosages, 24 tablets or 12,000 mg)
Study: NCT05628597

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fos Biomedical patch product
Description: Participants will apply a Fos Biomedical patch system (consisting of 2 single-use patches) on a daily basis for 12 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fos Biomedical patch product
Description: Participants will apply a Fos Biomedical patch system (consisting of 2 single-use patches) on a daily basis for 12 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fos Biomedical patch product:placebo
Description: Participants will apply a placebo patch system (consisting of 2 single-use patches) on a daily basis for 12 weeks.
Study: NCT05168995

Intervention type: DRUG
Intervention: BDP/FF NEXThaler® 100/6 micrograms
Description: BDP/FF NEXThaler® 100/6 maintenance treatment: one or two inhalations twice daily (one inhalation in the morning and one inhalation in the evening).~BDP/FF NEXThaler® 100/6 maintenance and reliever treatment (MART)
Study: NCT05993728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Project
Description: The Body Project prevention program is a body acceptance program to promote a healthy body image and prevent eating disorder onset.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Project
Description: The Body Project prevention program is a body acceptance program to promote a healthy body image and prevent eating disorder onset.
Study: NCT05393830

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Restriction
Description: Three nights of sleep restricted to 4 hours per night.
Study: NCT05628597

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fos Biomedical patch product:placebo
Description: Participants will apply a placebo patch system (consisting of 2 single-use patches) on a daily basis for 12 weeks.
Study: NCT05993728

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational control
Description: Participants randomized to the educational control condition will receive videos addressing body image and eating disorders
Study: NCT06243510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: apixaban
Description: Participants will be randomized to receive a prescription for prophylactic apixaban

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: Participants will be randomized to receive a prescription for prophylactic enoxaparin
Study: NCT04855201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bocidelpar
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT05180682

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gait Training
Description: the physical therapist will provide different protocol at different weeks in the following way.~first week: first fitting and initial Gait training second week: Specific Gait Training third week: Advance Gait Training fourth week: Functional Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: the physical therapist will provide different protocol at different weeks in the following way.~first week: first fitting and initial Gait training second week: Specific Gait Training third week: Advance Gait Training fourth week: Functional Training
Study: NCT06188715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 2 mg Oral Tablet
Description: Tablets of 2 mg moxidectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo MOX
Description: Placebo tablets for moxidectin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MOX
Description: Placebo tablets for moxidectin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ALB
Description: Placebo tablets for albendazole
Study: NCT05044182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression and drainage seton
Description: Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
Study: NCT05002946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-104
Description: single oral dose
Study: NCT06206616

Intervention type: BEHAVIORAL
Intervention: Gluten-free diet
Description: Pediatric patients affected by newly diagnosed Celiac Disease (CD) according to the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria will start a gluten-free diet (GFD), as normally expected for all CD patients. The assessment of adherence to the GFD will be carried out through the monthly compilation, by the children and/or their parents, of a specifically created and validated questionnaire.~Before and after the start of GFD enrolled patients will undergo an abdominal ultrasound to establish the presence and degree of hepatic steatosis.
Study: NCT05002946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-104
Description: single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Hydrochloride 50Mg Oral Tablet
Description: single oral dose
Study: NCT05887622

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium chloride supplement
Description: Subjects will receive 64 mmol of KCl on the high potassium/high sodium condition.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive a placebo capsule on the moderate potassium/low sodium diet and the moderate potassium/high sodium diet
Study: NCT05044182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression and drainage seton
Description: Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cutting seton
Description: Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cutting seton
Description: Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
Study: NCT04769830

Intervention type: OTHER
Intervention: Bowel sound
Description: The characteristic data of bowel sounds, such as 24-hour average intestinal rate, duration of gastrointestinal sounds, amplitude, maximum frequency and average frequency, were collected to observe the differences of intestinal sounds among different AGI grades.
Study: NCT05887622

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive a placebo capsule on the moderate potassium/low sodium diet and the moderate potassium/high sodium diet
Study: NCT05556122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intercostal nerve block
Description: General anesthesia and intercostal nerve block were performed. The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lateral intercostal nerve block
Description: lateral intercostal nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine + compound betamethasone
Description: The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine + compound betamethasone
Description: The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
Study: NCT04774510

Intervention type: OTHER
Group type: OTHER
Intervention: Diagnostic Test: optimized C-Arm Cone Beam Computed Tomography
Description: Optimized C-ARM CBCT using new geometry and a novel software can rapidly and accurately detected brain abnormalities and hemorrhagic complications for critical patients with acute stroke. This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the neuro angiography suite (NAS).
Study: NCT06411431

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Chest Tube Removal
Description: Subjects within the Early Removal group will have their chest tube removed if the following criteria are met on the morning of POD#1:~* ≤1 cm of apical pleural separation and no other areas of pleural separation~* No air leak~* No bloody output or concern for bleeding~* \< 400cc of drainage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chest Tube Removal
Description: Subjects within the Standard Removal group will have their chest tube removal on POD#2 if the following criteria are met on the morning of POD#1:~* ≤1 cm of apical pleural separation and no other areas of pleural separation~* No air leak~* No bloody output or concern for bleeding~* \< 400cc of drainage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apical Chest Tube
Description: A single apical chest tube will be placed and connected to a suction device at least -20 mmHg suction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apical Chest Tube
Description: A single apical chest tube will be placed and connected to a suction device at least -20 mmHg suction.
Study: NCT06519799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menstrual hygiene products
Description: The influence on the intimate health of each product will be evaluated. As you can't not use a menstrual product during menstruation, no control group is included

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menstrual hygiene products
Description: The influence on the intimate health of each product will be evaluated. As you can't not use a menstrual product during menstruation, no control group is included
Study: NCT05744388

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gliderite® shape modification
Description: The stylet will be more obtuse angle than the standard shape. The stylet will be lubricated also before being fitted inside the endotracheal tube. The blade will be introduced inside the mouth midline, the tube will be held from the upper third and introduced in the midline also sliding over the blade and introduced inside the glottis.
Study: NCT06226064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VES001
Description: VES001 is an oral, blood brain barrier penetrating ligand of sortilin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matching dosage form, indistinguishable from the active treatment will be used as the placebo treatment.
Study: NCT06173674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: The music intervention will consist of three components including:~1. Playlist composition Six music genres playlists will be offered to patients, including Classical Music, Country Music, Folk Music, Hymns and Reglious Music, Jazz and Swing Music, Popular/Easy Listening/RNB and Soundtrack Music. Patients can also add their favourite music to the list as well.~2. Music Intervention Delivery The general criteria for intervention delivery are:1) Each session lasts at least 20 minutes; 2) The music will be delivered by a comfortable, wireless, on/off switch noise-cancelling headphone; 3) The volume will be adjusted according to the patient's preference and controlled at 65dB or lower; 4) The order of music in the playlists will be decided by the patient; 5) Music will be delivered in inpatient room and/or waiting area before surgery/procedure.~3. Cleaning and infection of the equipment We will comply with guidelines on disinfection of materials in the hospital.
Study: NCT06098131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic
Description: Neurodynamic Slider and Tensioner Technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic
Description: Neurodynamic Slider and Tensioner Technique
Study: NCT05828381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: 300mg,sc,d1,q3w; for a total of 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 100mg/m2,ivgtt, D1、D8,q3w ,for a total of 2 cycles
Study: NCT05418517

Intervention type: PROCEDURE
Intervention: Tracheostomy
Description: temporary tracheostomy insertion

Intervention type: PROCEDURE
Intervention: Overnight intubation
Description: Patient who had overnight intubation
Study: NCT05828381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 vigtt D1 , q3w , for a total of 2 cycles
Study: NCT05960591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADEPTH
Description: ADEPTH sensor will be used for bore depth measurements during plate osteosynthesis procedures.
Study: NCT05043480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF
Description: Participants will receive pulsed electromagnetic fields (PEMF) exposure to alternate lower limbs weekly for 16 weeks. Participants will place alternate lower limb into the PEMF machine. Each lower limb will be exposed to 1.5mT magnetic field exposure for 10 mins once a week (total 10 min each week) for 16 weeks.
Study: NCT06382818

Intervention type: RADIATION
Group type: OTHER
Intervention: COHORT A
Description: IMRT radiotherapy on whole breast according to the investigator's decision among:~* Moderate whole breast hypofractionated RT according to the START B schema with Fixed Field IMRT Technique: 40.05 Gy in 15 daily fractions over 3 weeks and a Sequential boost (+ 16 Gy/8 fr) or (+13.5/5 fr) if applicable.~* Extreme whole breast hypofractionated RT according to :~  * The FAST schema: Once-a-week ultra-HypoRT with Fixed Field IMRT Technique, 28.5 Gy in 5 fractions in 5 weeks~ * The FAST-Forward schema: Very accelerated course of HypoRT with Fixed Field IMRT Technique, 26 Gy in 5 fractions in 5 consecutive days

Intervention type: RADIATION
Group type: OTHER
Intervention: COHORT B
Description: Breast radiotherapy according to the investigator's decision among:~* External partial VMAT: 40 Gy in 15 fractions to the partial breast only (tumorectomy bed).~* Exclusive Brachytherapy: 30.1 Gy in 7 fractions or 32.0 Gy in 8 fractions of high-dose-rate brachytherapy in 5 days or as 50 Gy of pulsed-dose-rate brachytherapy over 5 treatment days.~* Whole Breast Normo fractionated IMRT with Fixed Field IMRT Technique: 50 Gy in 25 daily fractions over 5 weeks +/- Sequential (+ 16 Gy/8fr) or SIB (60 Gy/25 fr) treatment for boost if applicable.

Intervention type: RADIATION
Group type: OTHER
Intervention: COHORT C
Description: Whole breast and nodes Hypofractionated VMAT and a localized simultaneous boost according to the HypoG01 schema protocol:~VMAT Technique, 42.3 Gy in 18 fractions on all target volume on 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fractions).

Intervention type: RADIATION
Group type: OTHER
Intervention: COHORT D
Description: Breast radiotherapy based on available clinical trials:~- Whole Breast and Nodes Hypofractionated VMAT with adaptive treatment (margin reduction): HypoG01 Schema with VMAT Technique, 42.3 Gy in 18 fractions on all target volume over 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fr) In case of patient refusal or technique unavailable, a standard treatment available in the center for this indication will be delivered.
Study: NCT04933019

Intervention type: GENETIC
Group type: OTHER
Intervention: Detection of Clinclidamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR
Description: Detection of Clindamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR
Study: NCT05911620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance elastography (MRE)
Description: Magnetic Resonance Imaging (MRI) imaging with low-frequency vibrations to create a visual map (elastogram) that shows stiffness of body tissues

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic resonance elastography (MRE)
Description: Magnetic Resonance Imaging (MRI) imaging with low-frequency vibrations to create a visual map (elastogram) that shows stiffness of body tissues

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance elastography (MRE)
Description: Magnetic Resonance Imaging (MRI) imaging with low-frequency vibrations to create a visual map (elastogram) that shows stiffness of body tissues
Study: NCT06079437

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cheer
Description: Maximum isometric contraction was performed with cheering.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The cold pressure test
Description: Maximum isometric contraction was performed with the cold pressure test.
Study: NCT05879692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: focused ultrasound
Description: focused ultra sound cavitation using a device of Mabel6 DUO Ultra Cavitation Technology system produced by DAEYANG MEDICAL COMPANY, KOREA will be applied on the abdominal region which extending bilaterally from the line extending from mid axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crest below.~the session of Focused Ultra Sound will take 25- 30 minutes, twice/week and with about three day intervals for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Caloric Diet (LCD) and a low (FODMAPs) diet
Description: The Low caloric diet (LCD) diet will be an equilibrated diet that had a caloric value 10% below the total metabolic expenditure (total energy expenditure) of each individual.~The low FODMAPs diet (LFD) is a diet low in fermentable oligo-, di-, mono- saccharides and polyols (FODMAPs).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Caloric Diet (LCD) and a low (FODMAPs) diet
Description: The Low caloric diet (LCD) diet will be an equilibrated diet that had a caloric value 10% below the total metabolic expenditure (total energy expenditure) of each individual.~The low FODMAPs diet (LFD) is a diet low in fermentable oligo-, di-, mono- saccharides and polyols (FODMAPs).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: aerobic exercise program under direct supervision at a frequency of 3 times/week for 12 weeks, in the form of walking on a treadmill for 30 minutes with moderate intensity (12-14) according to The Borg Rating of Perceived Exertion (RPE) scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: aerobic exercise program under direct supervision at a frequency of 3 times/week for 12 weeks, in the form of walking on a treadmill for 30 minutes with moderate intensity (12-14) according to The Borg Rating of Perceived Exertion (RPE) scale.
Study: NCT06503588

Intervention type: OTHER
Intervention: Guidelines promoting surgical abstention
Description: Guidelines promoting surgical abstention
Study: NCT05630807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: Bepirovirsen will be administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered.